Pancreatic Cancer Research

ResearcherUniversité de MontpellierActive in the last 2 years

Eric Assénat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8958-2793; OpenAlex author ID A5039119608. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 17

  1. A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102659↗
  2. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  3. GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRIN… Co-author DOI 10.1136/bmjopen-2025-104228↗
  4. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  5. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  6. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  7. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  8. Detection of soluble biomarkers of pancreatic cancer in endoscopic ultrasound-guided fine-needle aspiration samples. Last author DOI 10.1055/a-1550-2503↗
  9. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcino… Co-author DOI 10.1002/ijc.33225↗
  10. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinica… Co-author DOI 10.1016/j.esmoop.2021.100318↗
  11. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  12. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Co-author DOI 10.3390/cancers12040783↗
  13. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  14. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. Co-author DOI 10.1186/s12885-018-4906-4↗
  15. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1038/ctg.2016.18↗
  16. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "TH… Co-author DOI 10.18632/oncotarget.3473↗
  17. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmoa1011923↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc Ychou · 6 shared papers, 2011–2025 · strength 0.66
  2. Fabienne Portales · 4 shared papers, 2015–2025 · strength 0.59
  3. Sara Cherradi · 1 shared paper, 2026 · strength 0.39
  4. Hong Tuan Duong · 1 shared paper, 2026 · strength 0.39
  5. Pascal R. Hammel · 3 shared papers, 2016–2024 · strength 0.26
  6. Thierry Conroy · 3 shared papers, 2011–2024 · strength 0.23
  7. Jean‐Baptiste Bachet · 3 shared papers, 2011–2024 · strength 0.23
  8. Louis Buscail · 3 shared papers, 2016–2020 · strength 0.22
  9. Barbara Bournet · 3 shared papers, 2016–2020 · strength 0.22
  10. James Biagi · 2 shared papers, 2018–2024 · strength 0.21
  11. Olivier Bouché · 2 shared papers, 2011–2024 · strength 0.17
  12. Bertrand Napoléon · 2 shared papers, 2018–2020 · strength 0.16
  13. Stéphanie Truant · 2 shared papers, 2018–2020 · strength 0.16
  14. Cindy Canivet · 2 shared papers, 2018–2020 · strength 0.16
  15. Emmanuel Mitry · 1 shared paper, 2024 · strength 0.15
  16. Rémy Nicolle · 1 shared paper, 2024 · strength 0.15
  17. Vinciane Rebours · 1 shared paper, 2024 · strength 0.15
  18. Anthony Turpin · 1 shared paper, 2024 · strength 0.15
  19. Jerome F. Cros · 1 shared paper, 2024 · strength 0.15
  20. Nicolas Alejandro Fraunhoffer · 1 shared paper, 2024 · strength 0.15
  21. Brice Chanez · 1 shared paper, 2024 · strength 0.15
  22. Aurélien Lambert · 1 shared paper, 2024 · strength 0.15
  23. Daniel John Renouf · 1 shared paper, 2024 · strength 0.15
  24. Juan Iovanna · 1 shared paper, 2024 · strength 0.15
  25. Alexandre Harlé · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.